Jane Street Group, LLC Cor Medix Inc. Transaction History

Jane Street Group, LLC

$481 Billion
Q2 2025

A detailed history of Jane Street Group, LLC transactions in Cor Medix Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 285,960 shares of CRMD stock, worth $3.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

285,960

Previous 91,200 213.55%

Holding current value

$3.29 Million

Previous $561,000 527.99%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$5.86 - $16.56 $1.68 Million - $4.74 Million	285,960 New	285,960 $3.52 Million
Q4 2024 Feb 14, 2025	SELL	$8.1 - $13.59 $745,143 - $1.25 Million	-91,993 Reduced 77.4%	26,861 $217,000
Q3 2024 Nov 14, 2024	SELL	$3.64 - $8.23 $9,951 - $22,500	-2,734 Reduced 2.25%	118,854 $960,000
Q2 2024 Aug 14, 2024	BUY	$4.08 - $6.39 $414,254 - $648,795	101,533 Added 506.27%	121,588 $526,000
Q1 2024 May 15, 2024	SELL	$2.94 - $4.24 $128,051 - $184,673	-43,555 Reduced 68.47%	20,055 $85,000
Q4 2023 Feb 14, 2024	BUY	$3.0 - $4.01 $95,010 - $126,996	31,670 Added 99.15%	63,610 $239,000
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $114,984 - $142,452	31,940 New	31,940 $118,000
Q1 2023 May 15, 2023	BUY	$3.22 - $4.61 $308,740 - $442,016	95,882 New	95,882 $396,000
Q3 2021 Nov 16, 2021	SELL	$4.46 - $7.11 $53,435 - $85,184	-11,981 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.05 - $10.09 $145,502 - $242,664	-24,050 Reduced 66.75%	11,981 $82,000
Q1 2021 May 18, 2021	BUY	$6.84 - $17.58 $246,452 - $633,424	36,031 New	36,031 $360,000
Q4 2019 Feb 14, 2020	SELL	$4.96 - $7.75 $75,158 - $117,435	-15,153 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.38 - $9.69 $96,676 - $146,832	15,153 New	15,153 $97,000

Others Institutions Holding CRMD

# of Institutions

183

Shares Held

32.6M

Call Options Held

881K

Put Options Held

583K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $474M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Cor Medix Inc. Transaction History